Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$17.05 USD
-1.05 (-5.80%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $17.18 +0.13 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRPT 17.05 -1.05(-5.80%)
Will SRPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Other News for SRPT
Crossed Above 50 Day Moving Average appears for SRPT after 3.61% move
BMO Capital Remains a Hold on Sarepta Therapeutics (SRPT)
Is SRPT setting up for a drop? 50 Day Moving Average Resistance shows up after climbing 0.46%
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
Wall Street Analysts Are Bullish on Top Healthcare Picks